Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AS-S603 in Healthy Adults and Elderly
NCT06786676Phase 1Recruiting
- Sponsor
- Amyloid Solution
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing Test group (AS-S603) with Placebo group (2 arms). Primary endpoints: Number of adverse events, Maximum observed concentration and 4 more. Started May 2025; status: recruiting.
02
Drugs
AS-S603
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06786676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06786676.